ArticleOncoTargets and therapy2020
MicroRNA 885-5p Inhibits Hepatocellular Carcinoma Metastasis by Repressing AEG1.
Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- In Silico Identification of Dysregulated miRNAs TargetingDiseases (Basel, Switzerland) · 2024Article
- Role of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies.Stem cells international · 2024Review
- Hsa_circ_0102899 promotes epithelial-mesenchymal transition in non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- CircPTPRM accelerates malignancy of papillary thyroid cancer via miR-885-5p/DNMT3A axis.Journal of clinical laboratory analysis · 2022Article
- HIV-1 Tat and cocaine impact astrocytic energy reservoir influence on miRNA epigenetic regulation.Genomics · 2021Article
- Regulation of angiogenesis by microRNAs in cancer.Molecular medicine reports · 2021Review
- The ATO/miRNA-885-5p/MTPN axis induces reversal of drug-resistance in cholangiocarcinoma.Cellular oncology (Dordrecht, Netherlands) · 2021Article
- LncRNA HOXA-AS2 promotes glioblastoma carcinogenesis by targeting miR-885-5p/RBBP4 axis.Cancer cell international · 2021Article
- Correlations between stemness indices for hepatocellular carcinoma, clinical characteristics, and prognosis.American journal of translational research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is the third major cause of cancer-related death. Mounting evidence shows that microRNAs play critical roles in the initiation and progression of HCC and may potentially serve as diagnostic markers for HCC. METHODS AND
resultsIn the present study, we explored the biological effects of miR-885-5p on HCC progression. We performed flow cytometry analyses of miR-885-5p in HCC cell lines and identified miR-885-5p as a recurrence-related microRNA. Overexpression of miR-885-5p significantly inhibited cell migration, invasion, proliferation, angiogenesis and EMT. Then, the correlation of miR-885-5p and AEG1 were confirmed by using luciferase assays, quantitative real-time PCR analysis and Western blotting. It was subsequently confirmed that Astrocyte Elevated Gene1 (AEG1) was a direct target gene of miR-885-5p.
conclusionmiR-885-5p likely acts as a tumor suppressor by regulating AEG1, suggesting that miR-885-5p may be a potential biomarker and can be targeted in therapeutic strategies against HCC in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.